The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Drugs under investigation for patients with MF who have failed treatment with JAK inhibitors
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, gives an overview of agents that are currently being evaluated in patients with myelofibrosis (MF) who have failed treatment with JAK inhibitors, including parsaclisib, pelabresib, navitoclax, imetelstat, and navtedmadlin. This interview took place virtually.
Disclosures
Advisory boards for Novartis, Abbvie, BMS, AOP Orphan.
